Merrimack Pharmaceuticals, Inc.
MACK
4
|
$14.72
0.27%
27K
|
Health Technology
(0.0% 1d) (-0.1% 1m) (19.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1.18% volume)
Earnings Calendar:
Market Cap: $ 213,907,507
http://www.merrimackpharma.com
Sec Filling | Patents | n/a employees
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
cancer diagnostics treatment
add to watch list Paper trade email alert is off
Press-releases
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $52.6 -0.42% 380K
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | $87.02 0.99% 140K
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-11-09 (Crawled : 15:00) - biospace.com/
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: 215.75%
H: 8.16%
C: -0.95%
onivyde report pancreatic
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
Published: 2022-08-03 (Crawled : 13:20) - biospace.com/
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: -19.68%
H: 10.25%
C: 6.5%
onivyde report trial cancer
BioSpace Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena Oncology
Published: 2022-04-15 (Crawled : 13:00) - biospace.com/
AUTL | $4.73 -1.46% 99K
|
Health Technology
| Email alert
Add to watchlist
AVRO | $1.24 200
|
Health Technology
| Email alert
Add to watchlist
BLUE | $0.9601 0.75% 1.9M
|
Health Technology
| Email alert
Add to watchlist
EXEL | $22.41 -0.36% 530K
|
Health Technology
| Email alert
Add to watchlist
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
MACK 4 | $14.72 0.27% 27K
|
Health Technology
| Email alert
Add to watchlist
MSFT | News F | $402.515 -0.43% 9.5M
|
Technology Services
| Email alert
Add to watchlist
MRNA S | $102.68 0.67% 640K
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.24 1.87% 2M
|
Health Technology
| Email alert
Add to watchlist
BSX | $67.31 -0.16% 2.1M
|
Health Technology
| Email alert
Add to watchlist
Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round
Published: 2022-01-05 (Crawled : 17:00) - biospace.com/
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: 0.26%
H: 0.52%
C: -1.3%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.02%
H: 0.51%
C: -7.58%
therapeutics disease bioscience
Merrimack Reports Third Quarter 2021 Financial Results
Published: 2021-11-04 (Crawled : 22:00) - biospace.com/
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: -1.68%
H: 2.35%
C: 0.43%
financial results results
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
Published: 2021-06-15 (Crawled : 20:00) - biospace.com/
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: -0.62%
H: 1.41%
C: -0.47%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 6.31%
H: 2.2%
C: -1.32%
BioSpace Movers & Shakers, June 4
Published: 2021-06-04 (Crawled : 15:15) - biospace.com/
RDUS | $18.62 0.52% 23K
|
Health Technology
|
| O: 0.27%
H: 3.07%
C: -0.33%
OPT | $3.4 1.8K
|
Health Technology
|
| O: 3.77%
H: 1.85%
C: -0.86%
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: -0.16%
H: 0.94%
C: -0.47%
IGMS | $7.24 -2.29% 47K
|
Health Technology
|
| O: 2.14%
H: 1.89%
C: -0.8%
DRRX | $0.91 7.4K
|
Health Technology
|
| O: 0.0%
H: 3.57%
C: 2.38%
space spac
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
Published: 2021-05-28 (Crawled : 12:15) - globenewswire.com
ATNF | $1.84 0.55% 11K
|
|
| O: 5.25%
H: 14.71%
C: 2.58%
MACK 4 | $14.72 0.27% 27K
|
Health Technology
|
| O: 0.05%
H: 2.0%
C: 0.58%
life science
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
Published: 2015-02-26 (Crawled : 08:20) - globenewswire.com
MACK 4 | $14.72 0.27% 27K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.34 2.09% 620K
|
Health Technology
| Email alert
Add to watchlist
financial results results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.3022 24.82% 51M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 100K
|
Health Technology
|
14:00
CDZI P 25000 | $2.275 1.11% 74K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.47 1.4% 6.6K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $22.26 0.41% 180
|
Finance
|
21:00
QCRH P 118 | $56.105 1.25% 11K
|
Finance
|
18:01
VUZI P 7500 | $1.245 -1.19% 140K
|
Electronic Technology
|
18:00
RMCF | $3.5501 390
|
Consumer Non-Durables
|
20:10